Daily Stock Analysis, CNAT, Conatus Pharmaceuticals Inc, priceseries

Conatus Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.34
Close
4.15
High
4.34
Low
4.10
Previous Close
4.35
Daily Price Gain
-0.20
YTD High
7.50
YTD High Date
May 21, 2020
YTD Low
2.30
YTD Low Date
Mar 16, 2020
YTD Price Change
0.22
YTD Gain
5.55%
52 Week High
7.50
52 Week High Date
May 21, 2020
52 Week Low
2.30
52 Week Low Date
Mar 16, 2020
52 Week Price Change
1.45
52 Week Gain
53.64%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 19. 2016
19.60
Jan 6. 2017
48.91
12 Trading Days
149.56%
Link
LONG
Mar 24. 2017
48.20
Apr 5. 2017
53.80
8 Trading Days
11.63%
Link
LONG
Apr 6. 2017
56.00
May 3. 2017
77.60
18 Trading Days
38.57%
Link
LONG
Jun 23. 2017
51.00
Jul 17. 2017
64.36
15 Trading Days
26.19%
Link
LONG
Dec 15. 2017
42.70
Dec 28. 2017
45.97
8 Trading Days
7.66%
Link
LONG
Mar 2. 2018
61.20
Mar 14. 2018
64.94
8 Trading Days
6.11%
Link
LONG
May 29. 2018
37.70
Jun 21. 2018
50.51
17 Trading Days
33.99%
Link
LONG
Aug 22. 2018
41.30
Sep 5. 2018
50.57
9 Trading Days
22.46%
Link
LONG
Sep 18. 2018
47.00
Sep 28. 2018
53.09
8 Trading Days
12.96%
Link
LONG
Dec 31. 2018
17.30
Jan 14. 2019
18.48
9 Trading Days
6.79%
Link
LONG
May 5. 2020
4.73
May 6. 2020
5.06
1 Trading Days
7.13%
Link
LONG
May 11. 2020
4.30
May 21. 2020
5.42
8 Trading Days
26.15%
Link
Company Information
Stock Symbol
CNAT
Exchange
NasdaqGM
Company URL
http://www.conatuspharma.com
Company Phone
(858) 376-2600
CEO
Steven J. Mento
Headquarters
California
Business Address
16745 WEST BERNARDO DRIVE, Suite 200, San Diego, CA 92127
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001383701
About

Conatus Pharmaceuticals, Inc. is a biotechnology company that engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in Dan Diego, CA.

Description

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.